First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 58 GLP-1 1. GLP-1 treatment 59 2. GLP-1 market growth and market share 60 3. VictozaⓇ market share 4. GLP-1 vs OAD 62 63 REN YANXIA Ren has type 2 diabetes China 5. VictozaⓇ value growth and market share 64 6. GLP-1 pipeline 7. OzempicⓇ 8. GLP-1 market value in Regions 9. SUSTAIN 65 66 40 67 73-75 novo nordisk

View entire presentation